48 completed, 15 terminated, 13 unknown, 7 withdrawn. 27 Phase 4, 24 Phase 2, 17 Phase 3, 11 Not applicable, 9 Phase 1.
Follow Ranolazine: new trials by email Literature Review of Ranolazine trials Research Report on Ranolazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study Ranolazine - STEMI (ST Elevation MI) | Phase 2 / Phase 3 | Recruiting | Federico II University | 100 | 2026-02-01 | 2026-03-11 |
| Feasibility Trial for a Right Ventricular Failure Platform Trial Empagliflozin, Ranolazine - Pulmonary Hypertension, Right Ventricular Dysfunction | Phase 2 | Recruiting | University of Alberta | 30 | 2025-07-15 | 2026-10-15 |
| A Study of Ranolazine in ALS Ranolazine, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Recruiting | Swathy Chandrashekhar, MBBS | 72 | 2025-04-29 | 2026-06-08 |
| Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy Ranolazine, Placebo - Crohn's Disease, Inflammatory Bowel Disease | Phase 2 | Terminated | Vanderbilt University Medical Center | 4 | 2022-10-18 | 2025-02-06 |
| Ranolazine a Potential New Therapeutic Application Ranolazine, Placebo - Myocardial Stunning | Phase 4 | Withdrawn | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2019-04-10 | 2021-02-25 | |
| Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation Ranolazine plus Metoprolol Combination, FlecainidE pluS Metoprolol Combination - Atrial Fibrillation, Recurrence | Phase 2 / Phase 3 | Withdrawn | Elpen Pharmaceutical Co. Inc. | 2018-09-01 | 2019-05-13 | |
| Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis Ranolazine 500 MG, Ranolazine 1000 MG - ALS | Phase 2 | Completed | University of Kansas Medical Center | 14 | 2018-06-11 | 2024-12-09 |
| A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency Ranolazine, Placebos - Angina | Not applicable | Completed | TSH Biopharm Corporation Limited | 20 | 2018-06-07 | 2019-04-10 |
| Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine) Ranolazine - Chronic Stable Angina | Phase 4 | Unknown | OBS Pakistan | 2000 | 2018-04-01 | 2018-04-03 |
| RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain Ranolazine - Severe Coronary Artery Disease, Ischaemic Myocardial Dysfunction | Withdrawn | Saint Thomas Health | 2017-04-14 | 2018-04-10 | ||
| CiPA Phase 1 ECG Biomarker Validation Study Ranolazine, Verapamil, Lopinavir / Ritonavir - Drug-induced QT Prolongation, Pharmacokinetics | Phase 1 | Completed | Food and Drug Administration (FDA) | 60 | 2017-03-14 | 2020-01-18 |
| Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR) Ranolazine, Placebo - Angina | Phase 4 | Unknown | Amit Malhotra, MD | 40 | 2017-01-10 | 2017-02-07 |
| Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics Ranolazine, Placebo - Silent Myocardial Ischemia, Type 2 Diabetes | Not applicable | Withdrawn | Walter Reed National Military Medical Center | 2016-11-01 | 2017-05-17 | |
| Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die - HCM - Hypertrophic Non-Obstructive Cardiomyopathy | Phase 2 | Completed | IRCCS San Raffaele | 26 | 2016-10-01 | 2020-12-10 |
| Targeting Right Ventricle in Pulmonary Hypertension Gilead Ranolazine, Placebo - Pulmonary Hypertension | Phase 4 | Completed | University of Pennsylvania | 22 | 2016-07-01 | 2019-02-26 |
| A Study of Pharmacokinetics and Safety of Ranolazine PR in Healthy Korean and Caucasian Male Subjects Ranolazine - Healthy Male Individuals | Phase 1 | Unknown | A.Menarini Asia-Pacific Holdings Pte Ltd | 120 | 2016-03-01 | 2016-06-29 |
| Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome Ranolazine, Placebo - Stable Angina, Metabolic Syndrome | Phase 4 | Completed | University of Florida | 33 | 2015-09-01 | 2020-04-10 |
| Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents Ranolazine, Sugar pill - Angina | Phase 2 | Terminated | North Florida Foundation for Research and Education | 5 | 2015-08-01 | 2019-06-11 |
| Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries Ranolazine, Placebo - Myocardial Ischemia, Coronary Artery Disease | Phase 4 | Withdrawn | East Carolina University | 2015-06-01 | 2023-03-13 | |
| Ranolazine Mediated PVC Reduction in Ischemic Heart Disease ranolazine - Ventricular Premature Complexes, Myocardial Ischemia | Phase 2 | Completed | Kent Hospital, Rhode Island | 6 | 2014-12-01 | 2020-01-29 |
Showing 20 of 86. Sign in to see all of them.
Coronary Artery Disease (16) · Angina Pectoris (15) · Diabetes Mellitus, Type 2 (11) · Myocardial Ischemia (8) · Atrial Fibrillation (6) · Chest Pain (6) · Angina, Stable (5) · Hypertension, Pulmonary (5) · Arrhythmias, Cardiac (4) · Heart Failure (4) · Cardiomyopathies (3) · Ischemia (3) · Tachycardia, Ventricular (3) · Acute Coronary Syndrome (2) · Cardiovascular Diseases (2)
Gilead Sciences (18) · University of Roma La Sapienza (3) · Cedars-Sinai Medical Center (2) · Corewell Health East (2) · Duke University (2) · Food and Drug Administration (FDA) (2) · North Florida Foundation for Research and Education (2) · University of California, San Diego (2) · University of Pennsylvania (2) · University of Rochester (2) · Walter Reed National Military Medical Center (2) · A.Menarini Asia-Pacific Holdings Pte Ltd (1) · Amit Malhotra, MD (1) · Aspirus Heart and Vascular Institute-Research and Education (1) · Atlanta Heart Specialists, LLC (1)
United States (65) · Italy (8) · Israel (7) · Canada (6) · Czechia (6) · Germany (6) · Poland (6) · Russia (5) · Ukraine (4) · United Kingdom (4) · Hungary (3) · Serbia (3) · Slovakia (3) · South Africa (3) · Netherlands (2)
Patrick Yue, MD (4) · Anthony A Bavry, MD, MPH (2) · Carlos Sanabria, MD (2) · Francesco Pelliccia, MD (2) · Jeffrey Statland, MD (2) · Yuchi Han, MD (2) · Agostino G Ingraldi, M.D. (1) · Alan J Camm, Professor (1) · Amit Malhotra, MD (1) · Anthony DeMaria, MD (1) · Ashesh N Buch, MB.ChB, M.D. (1) · Axel Juan, MD (1) · Basmah Safdar, MD (1) · Bina Ahmed, MD (1) · Bojan Vrtovec, MD, PhD (1)
PMID 29531764, PMID 16875985, PMID 17456819, PMID 19349325, PMID 19371824, PMID 19389561, PMID 20298924, PMID 20357382, PMID 20385930, PMID 20644019, PMID 21538388, PMID 21565740, PMID 23500237, PMID 24481910, PMID 24530676, PMID 24621836, PMID 24628859, PMID 24852915, PMID 24978650, PMID 25054430, PMID 25210025, PMID 25249560, PMID 25602175, PMID 25760881, PMID 25870186, PMID 26049552, PMID 26059896, PMID 26226999, PMID 26324176, PMID 26401256, PMID 26474810, PMID 26555329, PMID 26614823, PMID 26697176, PMID 27733495, PMID 28036330, PMID 28036334, PMID 28081848, PMID 28213480, PMID 28473401, PMID 29263019, PMID 29938533, PMID 30071993, PMID 30293664, PMID 30390395, PMID 30447156, PMID 30771861, PMID 30909832, PMID 33272036, PMID 33518355
2025 (1)